Abstract: The invention relates to a pharmaceutical dosage form having a breaking strength of at least 300 N and comprising a pharmacologically active compound, an anionic polymer bearing carboxylic groups, wherein the content of the anionic polymer is ?20 wt.-%, based on the total weight of the pharmaceutical dosage form, and a nonionic surfactant.

Abstract: The present invention is directed to a tablet containing a 1-(?-D-glucopyranosyl)-3-(phenylthienylmethyl)benzene compound in high drug loading, in particular, containing the compound ranging from 30 to 95% by weight of tablet and pharmaceutically acceptable additives.

Abstract: Described herein are compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and anti-bacterial applications of such compositions. The sNAG nanofibers may be formulated into compositions for the prevention and/or treatment of bacterial infections and diseases associated with such infections. Regimens employing such compositions are also described.

Abstract: The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.

Abstract: The present invention relates to a fermented infant formulae comprising non digestible oligosaccharides for improving intestinal tract health by decreasing protein digestive effort, by decreasing the amount of endogenously formed proteases concomitant with an increased protein digestion, and a reduced protein fermentation.

Abstract: The present invention provides a process for preparing a particulate medicament that has greater homogeneity and a lower adhesion between the particles of the active ingredient and the carrier. The process comprises the steps of: (a) combining a pharmaceutically active ingredient in the form of an agglomerate of primary particles having an agglomerate particle size such that the agglomerate is capable of passing through a sieve having a mesh of 50-3000 .mu.m with a pharmaceutically acceptable particulate carrier, and (b) mixing the resultant material in a mixer to break up the agglomerate into primary particles dispersed in the pharmaceutically acceptable particulate carrier such that 90% or more of the pharmaceutically active ingredient exists as primary particles having a particle size of 50 .mu.m or less.

Abstract: An aqueous cosmetic or dermatological preparation for application on wet or moist skin which is substantially emulsifier-free and comprises at least two different polyacrylic acid polymers, at least two different C14-22 fatty alcohols, and at least about 13% by weight of microcrystalline wax, preferably in combination with one or more hydrocarbon oils.

Abstract: The invention relates to synergistically effective ternary antimicrobial mixtures.

Abstract: The invention relates to a solid cosmetic composition, in the form of a loose or compact powder, comprising: (a) from 50% to 99% by weight of at least one particulate solid phase, (b) from 0.5% to 50% by weight of at least one non-volatile liquid phase, and (c) from 0.01% to 4% by weight of at least one block copolymer obtained from a first monomer of 2-acrylamidomethylpropanesulphonic acid and from a vinyl second monomer having a nitrogenous cyclic side chain. The invention also relates to a process for manufacturing such a composition, which comprises: (i) mixing the particulate solid phase, the non-volatile liquid phase, the block copolymer and water so as to obtain a slurry, (ii) suctioning off the water present in the slurry so as to obtain a dry powder.

Abstract: This invention reports ciprofloxacin (CIP)-encapsulated polymeric nanoparticles and its antibacterial potential with a variety of gram positive and gram negative pathogenic bacteria. CIP-encapsulated nanoparticles of diethylaminoethyl cellulose (DEA-EC) are prepared by the multiple emulsion solvent evaporation method. CIP-encapsulated nanoparticles showed superior effectiveness to inhibit the growth of bacteria in-vitro.

Abstract: This invention provides a composition comprising: (i) a chitosan hydrogel comprising cross-linked chitosan and water; and (ii) a liquid dispersed in the hydrogel.

Abstract: The present invention provides methods, systems, and devices for performing photothermal therapy (e.g., to treat cancer) using photothermal nanoparticles with a biocompatible coating surrounding a highly crystallized Fe3O4 core. In certain embodiments, the highly crystallized Fe3O4 core of the photothermal nanoparticles has an X-ray diffraction (XRD) pattern where the brightest diffraction ring is from the 440 plane. In some embodiments, the photothermal therapy is conducted with a device configured to emit electromagnetic radiation in the wavelengths between about 650 nm and 1000 nm, wherein the device further comprises a visible light source that allows a user to determine where the electromagnetic radiation is contacting a subject.

Abstract: The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.

Abstract: The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.

Abstract: The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.

Abstract: The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT.

Abstract: A delivery device that allows for the sustained release of an agent, particularly useful for the sustained release of a therapeutic agent to limited access regions, such as the posterior chamber of the eye and inner ear. The delivery device is minimally invasive, refillable and may be easily fixed to the treatment area. The delivery device includes a hollow body with an inlet port at its proximal end for insertion of the agent, a reservoir for holding the agent and a delivery mechanism for the sustained delivery of the agent from the reservoir to the patient.

Abstract: The present invention relates to materials having therapeutic compositions releasably contained within the materials. The materials are configured to release therapeutic compositions at a desired rate. The present invention also relates to devices incorporating the materials.

Abstract: There is provided a novel water-in-oil type emulsified cosmetic comprising a diester of neopentylglycol with isononanoic acid. Said cosmetic exhibits not only the refreshed feeling on use without unfavorable stickiness after application, but also proper oily feeling. There are obtained good affinity to the skin, little occurrence of creasing and/or make-up deterioration, no oily sheen upon the elapse of long periods of time after application, and little irritation to the skin and excellent safety to the skin. In addition, the present cosmetic is able to be removed with commercially available cleansing agents. Moreover, the dispersibility of pigments as well as the storage stability is excellent. A water-in-oil type emulsified cosmetic comprising (A) 10 to 60 parts by mass of a diester represented by the following formula (I): (B) 1.0 to 11 parts by mass of a nonionic surfactant, (C) 0.3 to 11 parts by mass of an oil-soluble and/or water-soluble thickener, (D) 0.

Abstract: Suggested are alkoxylation products of 2-isopropyl-5-methyl-hexan-1-ol in which AO stands for an ethylene oxide, propylene oxide or butylenes oxide unit or their mixtures and n denominates an integer of from 1 to 100.